Skip to main content

Table 3 Patient’s characteristics according to the expression of combined NER (ERCC1, XPF and XPA) in primary tumour (n = 207)

From: Increased levels of XPA might be the basis of cisplatin resistance in germ cell tumours

 

Combined NER

Variable

N

Mean HS

SEM

Median

p value

All patients

207

282.6

10.1

280.0

NA

Histology

 Seminoma

38

202.2

22.9

205.0

***0.0004

 Non-seminoma

169

300.6

10.8

300.0

 

Tumour primary

 Primary TGCTs

200

279.9

10.2

270.0

*0.0500

 Extragonadal GCTs

7

387.0

63.4

360.0

 

IGCCCG risk group

 Good prognosis

158

266.4

11.3

260.0

**0.0062

 Intermediate

23

321.3

29.1

320.0

 

 Poor prognosis

26

358.3

30.4

345.0

 

Number of metastatic sites

 0

54

279.0

19.2

250.0

*0.0471

 1 to 2

124

271.0

12.9

270.0

 

  > 3

29

348.3

28.8

330.0

 

Retroperitoneal lymph nodes metastases

 Absent

61

282.7

18.3

250.0

0.6121

 Present

146

282.5

12.2

287.5

 

Mediastinal lymph nodes metastases

 Absent

189

277.9

10.5

270.0

0.1142

 Present

18

339.7

36.6

310.0

 

Lung metastases

 Absent

160

268.8

11.3

252.5

***0.0048

 Present

47

331.9

21.4

325.0

 

Liver

 Absent

197

278.5

10.3

270.0

0.0584

 Present

10

368.3

47.1

350.0

 

Non-pulmonary visceral metastases

 Absent

194

278.3

10.4

270.0

0.0661

 Present

13

354.5

42.7

345.0

 

S stage

 0

78

246.7

15.5

232.5

***0.0004

 1

78

283.1

15.8

285.0

 

 2

29

335.0

26.3

345.0

 

 3

16

385.7

36.5

362.5

 

 unknown

6

    
  1. Boldface p value denotes statistical significance < 0.05: *p < 0.05; **p < 0.01, ***p < 0.005
  2. NA Not applicable; TGCT Testicular germ cell tumour; GCT Germ cell tumour; IGCCCG International Germ Cell
  3. Consensus Classification Group; HS Histoscore; SEM Standard error of the mean